Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort-MedSci.cn

Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort

Monforte, AD; Lorenzini, P; Cozzi-Lepri, A; Mussini, C; Castagna, A; Baldelli, F; Puoti, M; Vichi, F; Maddaloni, A; Lo Caputo, S; Gianotti, N; Antinori, A

Monforte, AD (reprint author), Univ Milan, Dept Hlth Sci, ASST Santi Paolo & Carlo, Clin Infect & Trop Dis, Milan, Italy.

Abstract

Background: We aimed to mimic the ACTG 5257 trial, comparing raltegravir (RAL), ritonavir-boosted atazavavir (ATV/r) and ritonavir-boosted darunavir (......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort

科室

工具

服务